Sectors & IndustriesHealthcareMedical Devices

Best Medical Device Stocks to Buy Now (2025)

Top medical device stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best medical device stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best medical equipment stocks to buy right now are:

Livanova (NASDAQ:LIVN) is the #1 top medical device stock out of 142 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Livanova (NASDAQ:LIVN) is: Value: B, Growth: A, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: A.

Livanova (NASDAQ:LIVN) has a Due Diligence Score of 17, which is -10 points lower than the medical device industry average of 27. Although this number is below the industry average, our proven quant model rates LIVN as a "A".

LIVN passed 5 out of 33 due diligence checks and has weak fundamentals. Livanova has seen its stock return 6.92% over the past year, overperforming other medical device stocks by 41 percentage points.

Livanova has an average 1 year price target of $60.75, an upside of 11.41% from Livanova's current stock price of $54.53.

Livanova stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Livanova, 0% have issued a Strong Buy rating, 75% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Bioventus (NASDAQ:BVS) is the #2 top medical device stock out of 142 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: A, Growth: B, Momentum: D, Sentiment: B, Safety: B, Financials: B, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 21, which is -6 points lower than the medical device industry average of 27. Although this number is below the industry average, our proven quant model rates BVS as a "A".

BVS passed 7 out of 33 due diligence checks and has weak fundamentals. Bioventus has seen its stock lose -39.05% over the past year, underperforming other medical device stocks by -5 percentage points.

Bioventus has an average 1 year price target of $12.00, an upside of 73.16% from Bioventus's current stock price of $6.93.

Bioventus stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Bioventus, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Smith & Nephew (NYSE:SNN) is the #3 top medical device stock out of 142 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Smith & Nephew (NYSE:SNN) is: Value: B, Growth: B, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: C.

Smith & Nephew (NYSE:SNN) has a Due Diligence Score of 42, which is 15 points higher than the medical device industry average of 27.

SNN passed 15 out of 38 due diligence checks and has strong fundamentals. Smith & Nephew has seen its stock return 20.51% over the past year, overperforming other medical device stocks by 55 percentage points.

Smith & Nephew has an average 1 year price target of $36.00, a downside of -3.51% from Smith & Nephew's current stock price of $37.31.

Smith & Nephew stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Smith & Nephew, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 7 medical device stocks that have issued dividends in the past year, the 3 medical device stocks with the highest dividend yields are:

Smith & Nephew (NYSE:SNN) has an annual dividend yield of 2.01%, which is 1 percentage points higher than the medical device industry average of 0.98%. Smith & Nephew's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Smith & Nephew's dividend has shown consistent growth over the last 10 years.

Smith & Nephew's dividend payout ratio of 66.7% indicates that its dividend yield is sustainable for the long-term.

Abbott Laboratories (NYSE:ABT) has an annual dividend yield of 1.29%, which is the same as the medical device industry average of 0.98%. Abbott Laboratories's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Abbott Laboratories's dividend has shown consistent growth over the last 10 years.

Abbott Laboratories's dividend payout ratio of 29% indicates that its dividend yield is sustainable for the long-term.

Iradimed (NASDAQ:IRMD) has an annual dividend yield of 0.93%, which is the same as the medical device industry average of 0.98%.

Iradimed's dividend payout ratio of 39.3% indicates that its dividend yield is sustainable for the long-term.

Medical device stocks were down -0.82% in the last day, and down -0.47% over the last week. Co Diagnostics was the among the top losers in the medical devices industry, dropping -34.74% yesterday.

Co-Diagnostics shares are trading lower after the company announced a $3.8 million registered direct offering of 9.619 million shares at a price of $0.40 per share.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued medical device stocks right now are:

Inmode (NASDAQ:INMD) is the most undervalued medical device stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Inmode has a valuation score of 71, which is 56 points higher than the medical device industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Inmode's stock has dropped -14.05% in the past year. It has overperformed other stocks in the medical device industry by 20 percentage points.

Conmed (NYSE:CNMD) is the second most undervalued medical device stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Conmed has a valuation score of 57, which is 42 points higher than the medical device industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Conmed's stock has dropped -32.51% in the past year. It has overperformed other stocks in the medical device industry by 2 percentage points.

Adapthealth (NASDAQ:AHCO) is the third most undervalued medical device stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Adapthealth has a valuation score of 57, which is 42 points higher than the medical device industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Adapthealth's stock has dropped -22.45% in the past year. It has overperformed other stocks in the medical device industry by 12 percentage points.

49.04% of medical device stocks rated by analysts are a strong buy right now. On average, analysts expect medical device stocks to rise by 30.94% over the next year.

4.5% of medical device stocks have a Zen Rating of A (Strong Buy), 17.12% of medical device stocks are rated B (Buy), 45.95% are rated C (Hold), 26.13% are rated D (Sell), and 6.31% are rated F (Strong Sell).